ProxyMiner / Diff

Lantheus Holdings, Inc. LNTH

Comparing the 2025 proxy against the 2026 proxy.

← Back to Lantheus Holdings, Inc.

Compare

From (older)To (newer)

CEO total Δ

+$1,386,334

+176.0% year-over-year

Peer churn

Members added or dropped across all peer groups

Policy + metric churn

Disclosures whose value moved or appeared/disappeared

Peer groups

Peer disclosure

No peer groups were extracted from either filing.

Executive pay

Named executive compensation

Executive	Status	From	To	Δ Total	Δ %	Δ At-risk
Mary Anne HeinoExecutive Chairperson and Chief Executive Officer	ChangedCEO	$787,596 2024	$2,173,930 2025	+$1,386,334	+176.0%	+69.0 pp
Brian A. MarkisonFormer Chief Executive Officer	ChangedCEO	$13,400,697 2024	$13,919,738 2025	+$519,041	+3.9%	+1.0 pp
Daniel M. NiedzwieckiChief Administrative Officer, General Counsel and Corporate Secretary	Changed	$4,352,332 2024	$4,966,384 2025	+$614,052	+14.1%	+0.9 pp
Amanda M. MorganChief Commercial Officer	Changed	$2,808,706 2024	$3,304,547 2025	+$495,841	+17.7%	+1.3 pp
Robert J. Marshall, Jr.Chief Financial Officer and Treasurer	Changed	$5,434,796 2024	$5,194,964 2025	-$239,832	-4.4%	-1.1 pp
Paul M. BlanchfieldFormer President	Changed	$5,307,884 2024	$5,435,275 2025	+$127,391	+2.4%	-0.1 pp
Dr. Jean-Claude ProvostChief Science Officer	Removed	$3,485,343 2024	—	—	—	—
Dr. Ludger DinkelborgNamed executive	Added	—	$15,259,597 2025	—	—	—
Etienne MontagutFormer Chief Business Officer	Removed	$3,822,319 2024	—	—	—	—

Governance

Policy guardrails

change in control
Unchanged
Not extracted → Not extracted
“Payments upon Termination or Change of Control”
clawback
Unchanged
present → present
“Clawback Policy”
compensation committee
Unchanged
Talent and Compensation Committee → Talent and Compensation Committee
“Talent and Compensation Committee”
compensation consultant
Unchanged
independent → independent
“Independent Compensation Consultant”
hedging
Unchanged
prohibited → prohibited
“prohibition on hedging and pledging of Shares”
pledging
Unchanged
prohibited → prohibited
“Short Term Trading, Hedging and Pledging Prohibition”
stock ownership guidelines
Unchanged
present → present
“The ownership guidelines that apply to our NEOs are shown in the table below”

Performance markers

Metric facts

ceo pay ratio
Changed
66 to 1 → 79 to 1
Numeric delta: +13.00
“on grant date fair value. Based on the methodology employed, we estimated the PEO compensation attributable to Ms. Heino and Mr. Markison to be $1,605,217 and $13,702,648, respectively, resulting in total PEO compensatio…”
median employee compensation
Changed
$203,408 → $1,605,217
Numeric delta: +1401809.00
“as PEO were included in full based on grant date fair value. Based on the methodology employed, we estimated the PEO compensation attributable to Ms. Heino and Mr. Markison to be $1,605,217 and $13,702,648, respectively,…”
revenue
Changed
$1.058 billion → $1.0 million
Numeric delta: -1057000000.00
“individual and corporate tax consequences of the compensation plans. The Talent and Compensation Committee has considered the impact of the expense, which will be recognized by the Company in accordance with FASB ASC Top…”
say on pay
Added
Not extracted → 95%
“Advisory “Say on Pay” Vote”
annual incentive payout
Unchanged
225% → 225%
Numeric delta: 0.00
“The maximum payout under the 2025 Executive Bonus Plan is 225% of the target payout, representing the product of (i) a maximum of 150% of the target payout based on achievement of Company corporate performance objectives…”
time equity mix
Unchanged
Not extracted → Not extracted
“Unvested time-based RSUs will be forfeited.”

Narrative

CD&A prose similarity

Coarse measure of how much the compensation discussion text moved year-over-year. Not a substitute for reading the actual filings.

29% shingled-prose overlap between the two filings.

2025: 103,754 chars · 2026: 108,171 chars

Committee Report:74% overlap (579 → 571 chars)
Pay Ratio (Item 402(u)):2% overlap (2,965 → 1,499 chars)
Say-on-Pay proposal:63% overlap (2,696 → 3,101 chars)

2025 proxy on SEC ↗2026 proxy on SEC ↗

Narrative

What actually changed in the CD&A

Sentence-level diff between the two filings. New disclosures appear first, then sentences whose wording shifted, then sentences the prior year had that are no longer present.

258 new185 changed244 removed220 unchanged

changedThe CD&A also describes the process followed by the Talent and Compensation Committee for making pay decisions, and its rationale for specific decisions related to 2025. 2024.
changedOur NEOs for the year ended December 31, 2025, 2024,were:
newName Title Mary Anne Heino(1) Executive Chairperson and Chief Executive Officer Robert J.
newMarshall, Jr. Chief Financial Officer and Treasurer Dr. Ludger Dinkelborg(2) Head of Research and Development Amanda M.
changedMorgan Morgan(2)Chief Commercial Officer Daniel M.
newNiedzwiecki Chief Administrative Officer, General Counsel and Corporate Secretary Brian A.
newMarkison(3) Former Chief Executive Officer Paul M.
newBlanchfield(4) Former President
new(1) Ms. Heino was appointed as our Executive Chairperson of the Board and principal executive officer effective November 7, 2025.
newShe assumed the additional role of Chief Executive Officer, on an interim basis, on January 1, 2026.
new(2) Dr. Dinkelborg was appointed Head of Research and Development effective August 1, 2025, following our acquisition of Life Molecular Imaging Limited (now renamed as Lantheus Biosciences Ltd.) (“Life Molecular”) in July 2025.
new(3) Mr. Markison served as our principal executive officer through November 6, 2025 and as Chief Executive Officer until his retirement on December 31, 2025.
new(4) Mr. Blanchfield served as President until November 7, 2025.
changedWe are the leading radiopharmaceutical-focused company committed company,deliveringlife-changingscienceto enabling enableclinicians to Find, Fight and Follow disease to deliver better patient outcomes.
newWe made important progress in 2025 to shape and sharpen our strategic focus within the radiopharmaceutical industry.
newThe highlights include the following:
new• We took meaningful steps to further build out the portfolio of radiodiagnostic products we offer to the prostate cancer community.
new• During 2025, we maintained our leadership position in the prostate-specific membrane antigen (“PSMA”) positron emission tomography (“PET”) imaging space with PYLARIFY.
new• In August, we announced the FDA had accepted our New Drug Application (“NDA”) for a new formulation of piflufolastat F-18 PSMA PET imaging agent, which we believe will potentially enable increased patient access, supply resilience, and enhanced production efficiency.
newThe FDA approved the new formulation on March 6, 2026.
new• We advanced LNTH-2401, our Phase 3 ready, gastrin-releasing peptide receptor (“GRPR”) targeted radiodiagnostic for prostate cancer.
newGRPR is a biologically distinct target from PSMA and an estimated 15%-30% of prostate cancer patients do not express PSMA.
newLNTH-2401 has the potential to complement PSMA PET imaging by identifying disease in patients who may be PSMA-negative or equivocal, extending the addressable population while fitting within our existing prostate cancer franchise.
new• We advanced and expanded our radiopharmaceutical portfolio and capabilities with two complementary acquisitions.
new• In July, we completed the acquisition of Life Molecular and strengthened our nuclear medicine commercial portfolio with the addition of Neuraceq, our beta-amyloid-target PET radiodiagnostic, which now serves as the commercial cornerstone of our Alzheimer’s disease portfolio.
newThe acquisition also enhanced our capabilities across the radiopharmaceutical value chain.
changedLantheus 2026 2025Proxy Statement Executive Compensation 34 40
new• In April, we completed the acquisition of Evergreen, which added OCTEVY, a registrational-stage PET imaging agent targeting neuroendocrine tumors, to our pipeline.
newOCTEVY complements our therapeutic candidate PNT2003.
newThe acquisition also added additional assets to our portfolio and advanced our capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.
new• We also advanced our late-stage pipeline outside of prostate cancer to launch readiness.
new• In October, we announced the FDA had established a Prescription Drug User Fee Act (“PDUFA”) target action date of March 29, 2026 for OCTEVY (subsequently extended to June 29, 2026), our diagnostic kit for the preparation of Gallium 68 edotreotide injection, indicated for use with PET imaging for localization of somatostatin receptor-positive neuroendrocrine tumors in adult and pediatric patients.
new• In October, we announced the FDA had accepted our NDA for MK-6240, our F-18-labeled tau-targeted PET imaging agent.
newMK-6240 previously received Fast Track designation from the FDA for its potential to address an unmet medical need in Alzheimer’s disease diagnostics.
newThe FDA set a PDUFA target action date of August 13, 2026.
new• We completed the divestiture of our legacy single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies LLC (effective January 1, 2026), a decisive action taken to focus on PET radiodiagnostics and simplify our operating model.
new• We enhanced our systems, processes, policies and infrastructure that support our innovation, productivity, scale and positive employee experience
changedOur executive compensation program has three primary elements: base salary, annual cash incentives in accordance with our Executive Team Incentive Bonus Plan (the “2025 “2024Executive Bonus Plan”), and long-term equity incentives.
changedBased on our performance, and consistent with the design of our program, the Talent and Compensation Committee made the following executive compensation decisions for fiscal year 2025: 2024:
newArea Highlights Base Salary • Approved merit-based adjustments to our NEOs’ base salaries, except for Ms. Heino and Dr. Dinkelborg, implemented in March 2025 in normal course of our compensation cycle.
newMs. Heino’s base salary was established in November 2025 upon her appointment as our Executive Chairperson, and Dr. Dinkelborg’s base salary was established in August 2025 upon his appointment as our Head of Research and Development.
changedExecutive Bonus Plan • At the beginning of fiscal year 2025, 2024,approved the design of the 2025 2024Executive Bonus Plan (as described in detail under the heading “2025 “2024Executive Bonus Plan” below), which includes: below)that:¡ utilizedfinancial metrics consisting of Net Revenue and Bonus EPS, as well as certain strategic objectives; and ¡ establishedindividual performance assessment objectivesfor each NEO.
changed• In early 2026, 2025,the Talent and Compensation Committee reviewed our performance against our corporate metrics and strategic objectives, and each NEO’s performanceagainsttheirindividual performance assessment. objectives.
changedFollowing the Talent and Compensation Committee’s certification of results, our average payout to each NEO, excluding Ms. Heino and Mr. Blanchfield, Montagut,under the 2025 2024Executive Bonus Plan was 47% 124%of target.
changedLantheus 2026 2025Proxy Statement Executive Compensation 35 41
changedArea Highlights Equity Compensation • Granted annual equity awards to our NEOs, except for Ms. Heino and Dr. Dinkelborg Mr.Markison(as described below), in March 2025 2024consisting of 50% PSUs, 25% RSUs, and 25% stock options.
newMs. Heino and Dr. Dinkelborg received equity awards consisting of 50% RSUs and 50% stock options upon their respective appointments in November and August 2025.
newMs. Heino also received an equity award consisting of 50% RSUs and 50% stock options in May 2025 in connection with her service as our non-executive Chair of the Board.
changed• We continued to use relative Total Shareholder Return (“rTSR”) against the S&P 400 Health Care Index as the sole metric to measure performance under the 2025 2024PSUs.
newFor the 2025 PSUs, we added a provision that caps the payout at the target level of performance if our absolute Total Shareholder Return (“TSR”) is negative during the performance period.
changed• We increased equity award values for certain of our NEOs in 2025 2024in consideration of our strong performance and continued growth in 2024, 2023,as well as our market positioning relative to our peer group.
changed• For the PSU awards granted in 2023, 2022,we certified our three-year rTSR performance against the S&P 400 600Health Care Index, which resulted in the vesting of 162.8% 200%of the target number of Shares subject to those PSU awards.
changedExecutive Benefits • Offered key employees, including our NEOs, the opportunity to participate in Adoptedthe Lantheus Nonqualified Deferred Compensation Plan (the “LDCP”) as inJuly2024toprovidekeyemployees,includingourNEOs,an additional option opportunityfor personal financial planning.
new• Offered financial advisory services and an executive physical health program to our key executives, including our NEOs.
newAdvisory “Say on Pay” Vote
changedEach year, we carefully consider the results of our shareholder “say on pay” “say-on-pay”vote from the preceding year.
changedAt our 2025 2024Annual Meeting of Shareholders, approximately 95% 97%of the votes were cast in favor of the compensation of our NEOs, as disclosed in our 2025 2024Proxy Statement.
changedThe Talent and Compensation Committee considered the results of the 2025 2024shareholder advisory vote on executive compensation when determining our 2026 2025executive compensation and will continue to consider our say on pay say-on-payresults, as well as feedback we receive throughout the year when making decisions about our executive compensation program.
changedLantheus 2026 2025Proxy Statement Executive Compensation 36 42
changedThe core philosophy of our executive compensation program is to support our primary objective of being the leading radiopharmaceutical-focused company committed aproviderofinnovativediagnostics,radiotherapeutics,andartificialintelligencesolutionsdesignedto enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes.
changedFurther, the Talent and Compensation Committee is committed to a program that contains a strong link between achieving our financial and strategic objectives, with andcompensation earned or awarded to further reflect our commitment to reinforce supportthis culture.
changedLantheus 2026 2025Proxy Statement Executive Compensation 37 43
changedLantheus 2026 2025Proxy Statement Executive Compensation 38 44
changedPay Element PaymentForm PaymentFormDescription/Objectives Timing Fixed Base Salary Cash Fixed amount to attract and retain executive talent needed to achieve our Company objectives and strategy.
changedGenerally granted at the time of hire orpromotion,and annually following the close of the previous fiscal year.
changed2025 2024Total Target Compensation Pay Mix
changedOur 2025 executive compensation 2024program maintained an emphasis on long-term equity incentives, which represented the largest percentage of total target compensation for our NEOs for 2025. 2024.
changedThe charts below show the mix of 2025 2024total target compensation for Mr. Markison, who hasserved as our CEO during 2025, sinceMarch2024,and our average for other NEOs.
newTarget compensation levels for Ms. Heino and Dr. Dinkelborg are not included, given neither were full participants in our annual compensation programs in 2025.
changedLantheus 2026 2025Proxy Statement Executive Compensation 39 45
changed• administering our equity-based compensation and overseeing design equityand implementation of our cash incentive compensation plans, including authorizing and granting awards under these plans, and monitoring compliance by management with those rules, policies and guidelines for the issuance of awards pursuant to those plans as established by the Talent and Compensation Committee or the Board;
changedLantheus 2026 2025Proxy Statement Executive Compensation 40 46
changedFor 2025, 2024,our Talent and Compensation Committee engaged Pearl Meyer as its independent compensation consultant.
changedIn July 2025, 2024,the Talent and Compensation Committee conducted an in-depth assessment of our 2024 2023peer group to evaluate if those companies have kept pace with the change to our business and the evolving market for talent in which we compete.
changedAt the recommendation of Pearl Meyer, the Talent and Compensation Committee identified appropriate changes to our 2025 2024peer group based on the following criteria:
changedScreening Criteria Description Industry U.S.-based publicly traded companies in the commercial biotechnology, pharmaceutical, health care healthcaresupplies, and life science tools and services industries Size 1/3x to 3x Lantheus’ trailing 12 months revenue and market capitalization and fewer than 10,000 employees Other Prioritized companies with similar size and valuation characteristics and considered (i) companies with a focus in diagnostics, imaging, injectable products, and/or oncology indications, (ii) companies with a Massachusetts headquarters, (iii) companies considered peers by shareholder advisory firms, and (iv) companies that are frequent peers of our peers
changedBased on the screening criteria and other factors previously mentioned, Pearl Meyer recommended, and the Talent and Compensation Committee approved, one change minorchangesto our peer group for 2025, 2024,which resulted in the replacement removalof Natera (NTRA) with Acadia 10xGenomics(TXG)andAmphastarPharmaceuticals (ACAD). (AMPH)andtheadditionofApellisPharmaceuticals(APLS)andWaters(WAT).
changedLantheus 2026 2025Proxy Statement Executive Compensation 41 47
newPeer Group Statistics Revenue Market Capitalization 75th Percentile $ 2,756M $10,866M 50th Percentile $ 1,874M $ 6,848M 25th Percentile $ 1,018M $ 3,949M Lantheus $ 1,526M $ 5,702M
changed* For both Lantheus and peers, revenue is based on publicly available trailing four quarters data information, generally as of March 31, 2025, 2024,and market capitalization is as of July 8, 2025 11,2024(the date on which Pearl Meyer formulated its recommended peer group).

Removed from 2025

NEO Title Brian A.
Markison(1) Chief Executive Officer Robert J.
Marshall, Jr. Chief Financial Officer and Treasurer Paul M.
Blanchfield President Amanda M.
Niedzwiecki Chief Administrative Officer, General Counsel and Corporate Secretary Dr. Jean-Claude Provost(3) Chief Science Officer Mary Anne Heino(4) Former Chief Executive Officer Etienne Montagut(5) Former Chief Business Officer
(1) Mr. Markison, became CEO of the Company and its subsidiaries effective March 1, 2024.
Mr. Markison served as Executive Chairman from January 23, 2024, to March 1, 2024, and as non-executive Chair of the Board prior to January 23, 2024.
(2) Ms. Morgan was promoted to Chief Commercial Officer effective March 25, 2024.
She previously served as Senior Vice President of Commercial since November 2022.
(3) Dr. Provost served as Chief Medical Officer until May 28, 2024 and transitioned to Chief Science Officer on the same date.
At the time of the transition, the Board determined that Dr. Provost was no longer an “executive officer” within the meaning of Rule 3b-7 of the Exchange Act or an “officer” within the meaning of Rule 16a-1(f) of the Exchange Act.
(4) Ms. Heino served as CEO of the Company and its subsidiaries until March 1, 2024.
She now serves as the non-executive Chair of the Board.
(5) Mr. Montagut served as Chief Business Officer until May 30, 2024.
Effective May 30, 2024, Mr. Montagut serves as a consultant and is no longer an “executive officer” within the meaning of Rule 3b-7 of the Exchange Act or an “officer” within the meaning of Rule 16a-1(f) of the Exchange Act.
We classify our products into three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.
• Our leading Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer.
• Our leading Precision Diagnostic products assist HCPs to Find and Follow diseases, with a focus on cardiology.
• Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically.
2024 was another stellar year for our Company, highlighted by the following:
• We exceeded our Net Revenue and Bonus Earnings per Share (“Bonus EPS”) (each set forth under the heading “2024 Executive Bonus Plan–Corporate Performance Factor and Actual Achievement” below) targets for the year, as adjusted in December 2024 and further described below.
• We maintained revenue growth and market leadership with PYLARIFY in the United States, with PYLARIFY revenues in 2024 reaching approximately $1.058 billion, an increase of 24.3% over 2023, and becoming the first ever blockbuster radiodiagnostic.
• We enhanced our manufacturing footprint, capacity and redundancy across our positron emission tomography (“PET”) manufacturing facilities (“PMFs”) network by qualifying 8 additional sites in 2024, for a total of 62 sites activated as of December 31, 2024.
• We maintained our market leadership with our Microbubble platform, as DEFINITY delivered record revenue in 2024 of approximately $317.8 million, representing an increase of 13.6% over 2023.
• In March 2024, we received FDA approval of a supplemental new drug application (“sNDA”) for the use of DEFINITY in pediatric patients with suboptimal echocardiograms, and we have subsequently launched DEFINITY for such use.
• We executed a series of strategic in-licensing deals and acquisitions, including:
• the acquisition of Meilleur Technologies Inc., including its asset NAV-4694, an investigational late-stage F-18-PET imaging agent that targets beta amyloid in Alzheimer’s disease.
• exclusive global licenses from Radiopharm Theranostics Limited for both a monoclonal antibody that targets LRRC15, a preclinical therapeutic candidate targeting osteosarcoma, and a Trophoblast cell surface antigen 2 (“TROP2”)-targeted nanobody, a preclinical stage therapy.
• global license from Life Molecular Imaging Ltd. (“Life Molecular”) for its clinical stage RM2, a gastrin-releasing peptide receptor-targeting agent, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair.
• We progressed two major transactions that led to the signing in January 2025 of definitive agreements to acquire Life Molecular and Evergreen Theragnostics, Inc., both of which are subject to customary closing conditions.
• During 2024, we developed and retained the talent and expertise we have within our organization and successfully recruited key new hires to ensure we have the needed talent to meet our strategic objectives.
Area Highlights Base Salary • Approved adjustments to our NEOs’ base salaries, except for Mr. Markison, in early 2024, which were implemented on March 25, 2024.
Mr. Markison’s base salary was established in January 2024 upon his appointment as our Executive Chairman and was maintained at the same level upon his appointment as our CEO in March 2024.
• In December 2024, the Talent and Compensation Committee approved minor adjustments to the threshold, target, and maximum performance levels for Net Revenue and Bonus EPS to account for the impact of certain events that occurred during 2024 that were not anticipated when the original performance levels were established (i.e., the acquisition of Meilleur Technologies, Inc. and in-licensing deals).
The adjustments resulted in a minor increase in payout levels for all our NEOs compared to the payout levels that would have been attained with the original performance levels.
Pursuant to the terms of Mr. Markison’s employment agreement, his initial equity award granted upon hire consisted of 50% PSUs and 50% RSUs.
Beginning in 2025, Mr. Markison’s annual equity award will consist of the same mix as provided to our other executive officers.
• For the PSUs awarded in March 2025, which are based 100% on rTSR performance, the payout level will be capped at the target level of performance if our absolute Total Shareholder Return (“TSR”) is negative during the performance period.
• Adopted financial advisory services and executive physical health programs in 2024 in which key executives, including our NEOs, are eligible to participate.
Stock Ownership Guidelines • Following a review of market practices, and to further enhance the alignment of our executive officers’ and shareholders’ interests, we increased our stock ownership guidelines from 3x to 6x base salary for our CEO and from 1x to 2x base salary for our other executive officers.
See the Stock Ownership and Retention Guidelines section of this Proxy Statement for more information.
Advisory “Say-on-Pay” Vote
Target compensation levels for Ms. Heino and Mr. Montagut are not included, given they both ceased to be employed by the Company in 2024.
(2) Excludes a retention RSU award granted to Dr. Provost in June 2024.
Peer Group Statistics Revenue Market Capitalization 75th Percentile $ 2,492M $14,179M 50th Percentile $ 1,565M $ 8,323M 25th Percentile $ 936M $ 6,608M Lantheus $ 1,366M $ 8,568M
NEO Base Salary at December 31, 2023 Base Salary at December 31, 2024 % Change Brian A.
Markison(1) N/A $950,000 N/A Robert J.
Marshall, Jr. $650,000 $676,000 4.0 % Paul M.
Blanchfield $650,000 $676,000 4.0 % Amanda M.
Morgan(2) $450,000 $525,015 16.7 % Daniel M.
Niedzwiecki $540,000 $561,600 4.0 % Dr. Jean-Claude Provost(3) $540,000 $556,200 3.0 % Mary Anne Heino(4) $886,000 N/A N/A Etienne Montagut(5) $575,000 N/A N/A
Mr. Markison’s 2024 base salary was established upon his appointment as our Executive Chairman on January 23, 2024, and no additional adjustment was made when he was appointed as our CEO on March 1, 2024.
(2) Ms. Morgan’s 2024 base salary increase was in connection with her promotion to our Chief Commercial Officer in March 2024.
(3) Dr. Provost served as Chief Medical Officer until May 28, 2024, and transitioned to Chief Science Officer on the same date.
At the time of the transition, the Board determined that Dr. Provost was no longer an “executive officer” within the meaning of Rule 3b-7 of the Exchange Act or an “officer” within the meaning of Rule 16a-1(f) of the Exchange Act.
(4) Ms. Heino was no longer an employee of the Company as of December 31, 2024.
She did not receive a salary increase in 2024 prior to her transition to our non-executive Chair of the Board.
He did not receive a salary increase in 2024 prior to his departure.
The Talent and Compensation Committee set the following target bonus opportunities for each NEO for 2024:
NEO(1) Base Salary at December 31, 2024 Target Bonus (% Salary) Target Bonus Brian A.
Markison $950,000 100 % $950,000 Robert J.
Marshall, Jr. $676,000 75 % $507,000 Paul M.
Blanchfield $676,000 60 % $405,600 Amanda M.
Niedzwiecki $561,600 50 % $280,800 Dr. Jean-Claude Provost $556,200 50 % $278,100
The performance range established for Net Revenue was 90% of target for threshold performance and 110% of target for maximum performance, consistent with the range used in 2023.
After a review of market practices and consideration of other factors, the Talent and Compensation Committee approved widening the performance range for Bonus EPS in 2024 to 85% of target for threshold performance and 115% of target for maximum performance.
Performance Metric Weighting Threshold Performance (50% Payout) Target Performance (100% Payout) Maximum Performance (150% Payout) Net Revenue(2) 40 % $1,319M $1,465M $1,612M Bonus EPS(3) 30 % $5.02 $5.91 $6.79
Based on the three strategic objectives approved by the Talent and Compensation Committee at the
Strategic Objective Achievement Rating Grow PSMA PET market and strengthen PYLARIFY brand leadership • Delivered full year PYLARIFY revenue above targeted amount.
Exceeded expectations • PYLARIFY revenue market share slightly below targeted percentage.
Below expectations • Activated additional PMFs, bringing our total up to 62 activated sites as of December 31, 2024.
Achieved expectations • Achieved our targeted batch efficiency doses per batch for PYLARIFY.
Achieved expectations • On track with respect to our Process Performance Qualification (PPQ) timeline.
Achieved expectations • CMS implemented its final rule that created separate payment for radiodiagnostics in 2025; we entered into strategic partnerships with a vast majority of our hospital and free-standing imaging business.
Exceeded expectations Solidify our Cardiology Franchise • Delivered full year DEFINITY revenue above targeted amount.
Exceeded expectations • Increased DEFINITY dose market share in the United States.
Exceeded expectations • Received FDA approval of our sNDA for the use of DEFINITY in pediatric patients with suboptimal echocardiograms in March 2024, and we subsequently launched DEFINITY for such use.
Achieved expectations • Progressed the automation of our manufacturing on time and at the budgeted cost.
Achieved expectations Progress PNT2002 clinical plan and prepare for future new drug application (“NDA”) submission • Progressed manufacturing and test method qualifications for PNT2002.
Achieved expectations • Announced the second interim analysis for SPLASH, which performed at 75% of protocol pre-specified overall survival events demonstrated results for both rPFS and OS that did not materially change from our previous interim analysis at 46% of pre-specified OS events in 2023.

More changes truncated for legibility. Open the filings on SEC for full prose.

Cells reading “Not extracted” mean the deterministic extractor didn’t pick up that disclosure for the listed filing — not that it isn’t in the proxy. Open the company workspace and use Ask to query the CD&A directly.